Sprott Inc
Change company Symbol lookup
Select an option...
SII Sprott Inc
GDRX Goodrx Holdings Inc
OXM Oxford Industries Inc
BV Brightview Holdings Inc
ARKG ARK Genomic Revolution ETF
BWA Borgwarner Inc
RCG RENN Global Entrepreneurs Fund, Inc.
SPI SPI Energy Co Ltd
CLH Clean Harbors Inc
CNLMF Collective Mining Ltd
Go

Financials : Capital Markets | Small Cap Blend
Based in Canada
Company profile

Sprott Inc. is an alternative asset management company. The Company is focused on providing investors with specialized investment strategical solutions. The Company’s operating segments include Exchange Listed Products, Managed Equities, Lending, Brokerage and Corporate. The Exchange Listed Segment offers closed-end physical trusts and exchange-traded funds (ETFs) products. The Managed Equities segment offers alternative investment strategic solutions for managed in-house and on a sub-advised basis. The Company offers its lending services primarily through limited partnership vehicles. The Company is also engaged in regulated broker-dealer activities primarily equity origination, corporate advisory, sales and trading activities in the United States and Canada. The Company’s subsidiaries include Sprott Asset Management LP (SAM), Sprott Capital Partners LP (SCP), Sprott Asia LP (Sprott Asia), Sprott Korea Corporation (Sprott Korea), Sprott Resource Lending Corp. (SRLC) and Sprott Inc.

Price
Delayed
$44.54
Day's Change
0.11 (0.25%)
Bid
--
Ask
--
B/A Size
--
Day's High
44.83
Day's Low
43.90
Volume
(Heavy Day)

Today's volume of 21,385 shares is on pace to be much greater than SII's 10-day average volume of 78,313 shares.

21,385

SPPI INVESTOR LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.

12:30 pm ET October 8, 2021 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / October 8, 2021 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ:SPPI) from December 27, 2018 through August 5, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the District of Nevada alleges violations of the Securities Act of 1934.

Image: https://www.accesswire.com/logos/thumbs/5184.jpg

If you purchased Spectrum securities, and/or would like to discuss your legal rights and options please visit Spectrum Shareholder Class Action Lawsuit or contact RujulPatel toll free at (877) 779-1414 or rpatel@bernlieb.com

According to the complaint, Spectrum issued materially false and/or misleading statements and failed to disclose adverse facts pertaining to the quality and integrity of the scientific data supporting the company's claims of efficacy for its drug ROLONTIS (eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia, which were known to, or recklessly disregarded by, the Defendants as follows: (a) the ROLONTIS manufacturing facility maintained deficient controls and/or procedures; (b) the foregoing deficiencies decreased the likelihood that the U.S. Food and Drug Administration ("FDA") would approve the ROLONTIS Biologics License Application ("BLA") as submitted in December 2018 in its current form; (c) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (D) as a result, the Company's public statements were materially false and misleading at all relevant times.

On August 6, 2021, Spectrum announced receipt of a Complete Response Letter ("CRL") from the FDA regarding the ROLONTIS BLA. The CRL cited deficiencies related to manufacturing and indicated that a reinspection of the Company's manufacturing facility will be necessary.

On this news, the price of Spectrum shares fell $0.70 per share, or 21.54%, to close at $2.55 per share on August 6, 2021.

If you wish to serve as lead plaintiff, you must move the Court no later than November 1, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased Spectrum securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/spectrumpharmaceuticalsinc-sppi-shareholder-class-action-lawsuit-fraud-stock-437/apply/ or contact Rujul Patel toll free at (877) 779-1414 or rpatel@bernlieb.com

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2021 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Rujul Patel

Bernstein Liebhard LLP

https://www.bernlieb.com

(877) 779-1414

rpatel@bernlieb.com

SOURCE: Bernstein Liebhard LLP

View source version on accesswire.com:

https://www.accesswire.com/667298/SPPI-INVESTOR-LAWSUIT-FILING-DEADLINE-Bernstein-Liebhard-LLP-Reminds-Investors-of-the-Deadline-to-File-a-Lead-Plaintiff-Motion-in-a-Securities-Class-Action-Lawsuit-Against-Spectrum-Pharmaceuticals-Inc

comtex tracking

COMTEX_394794665/2457/2021-10-08T12:30:13

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.